Nektar Therapeutics Variable Lease, Cost
Nektar Therapeutics (NKTR) reported Variable Lease, Cost of $7.91 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-03-13
- Nektar Therapeutics variable lease, cost for the quarter ending 2019-12-31 was $1.87M, a 65.99% increase year-over-year.
- Nektar Therapeutics variable lease, cost for the quarter ending 2019-09-30 was $1.49M, a 35.49% increase year-over-year.
- Nektar Therapeutics variable lease, cost for the quarter ending 2019-06-30 was $1.78M, a 50.68% increase year-over-year.
- Nektar Therapeutics variable lease, cost for the quarter ending 2019-03-31 was $1.27M, a 16.47% increase year-over-year.
- Nektar Therapeutics variable lease, cost for fiscal 2025 was $7.91M, a 12.17% decline from fiscal 2024.
- Nektar Therapeutics variable lease, cost for fiscal 2024 was $9.00M, a 28.08% increase from fiscal 2023.
- Nektar Therapeutics variable lease, cost for fiscal 2023 was $7.03M, a 34.33% decline from fiscal 2022.
- Nektar Therapeutics variable lease, cost for fiscal 2022 was $10.70M, a 19.23% increase from fiscal 2021.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $7.91M 10-K · filed 2026-03-13 | |||
| 2024-12-31 | $9.00M 10-K · filed 2026-03-13 | |||
| 2023-12-31 | $7.03M 10-K · filed 2025-03-14 | |||
| 2022-12-31 | $10.70M 10-K · filed 2024-03-05 | |||
| 2021-12-31 | $8.97M 10-K · filed 2024-03-05 | |||
| 2020-12-31 | $8.18M 10-K · filed 2023-02-28 | |||
| 2019-12-31 | $1.87M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $3.35M derived: sum of 2 quarters · filed 2022-03-01 | $5.13M derived: sum of 3 quarters · filed 2022-03-01 | $6.41M 10-K · filed 2022-03-01 |
| 2019-09-30 | $1.49M 10-Q · filed 2019-11-07 | $3.27M derived: sum of 2 quarters · filed 2019-11-07 | $4.54M 10-Q · filed 2019-11-07 | $5.67M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $1.78M 10-Q · filed 2019-08-09 | $3.05M 10-Q · filed 2019-08-09 | $4.18M derived: sum of 3 quarters · filed 2021-02-26 | $5.28M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $1.27M 10-Q · filed 2019-05-09 | $2.40M derived: sum of 2 quarters · filed 2021-02-26 | $3.50M derived: sum of 3 quarters · filed 2021-02-26 | $4.68M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $2.22M derived: sum of 2 quarters · filed 2021-02-26 | $3.40M derived: sum of 3 quarters · filed 2021-02-26 | $4.50M 10-K · filed 2021-02-26 |
| 2018-09-30 | $1.10M 10-Q · filed 2019-11-07 | $2.28M derived: sum of 2 quarters · filed 2019-11-07 | $3.37M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $1.18M 10-Q · filed 2019-08-09 | $2.27M 10-Q · filed 2019-08-09 | ||
| 2018-03-31 | $1.09M 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | $3.08M 10-K · filed 2020-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |